Filing summary
Important identity discrepancy: The request identifies Jade Biosciences, Inc., but the supplied 10-Q is for Aerovate Therapeutics, Inc. (Nasdaq: AVTE). The figures and disclosures below summarize the supplied Aerovate filing and should not be attributed to Jade Biosciences without verification.
Business context and reporting period
This unaudited Form 10-Q covers the quarter ended March 31, 2023; it was signed May 15, 2023. Aerovate is a clinical-stage biopharmaceutical company developing AV-101, an inhaled dry-powder formulation of imatinib for pulmonary arterial hypertension (PAH). It has no approved products and no product revenue. Its global IMPAHCT Phase 2b/Phase 3 trial was enrolling patients.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $13.5 million | $7.3 million |
| General and administrative expense | $4.2 million | $3.8 million |
| Total operating expenses | $17.6 million | $11.0 million |
| Net loss | $16.5 million | $10.9 million |
| Net loss per share, basic and diluted | $0.67 | $0.45 |
| Cash used in operating activities | $11.4 million | $5.7 million |
Interest income was $1.1 million, up from $0.1 million. Comprehensive loss was $16.3 million, including a $0.3 million unrealized investment gain. The filing does not report a meaningful operating margin because the company had no revenue and reported operating losses.
At March 31, 2023, cash and cash equivalents were $26.6 million and short-term investments were $92.4 million, totaling $118.9 million. Current assets were $120.6 million versus current liabilities of $10.6 million. Total liabilities were $11.3 million, principally accounts payable, accruals and lease liabilities; the company reported no long-term debt. Stockholders’ equity was $113.1 million. Management estimated existing cash and investments would fund planned operations into the second half of 2025, subject to risks and changing assumptions.
Changes versus the prior comparable period
- Operating expenses increased $6.6 million, or about 60%; R&D rose $6.2 million, mainly from clinical-trial costs and headcount associated with the ongoing Phase 2b/Phase 3 trial.
- Net loss increased $5.6 million. Higher interest income partly offset increased operating expenses.
- Operating cash use increased $5.8 million. Cash and investments together declined from $129.2 million at December 31, 2022 to $118.9 million at March 31, 2023.
- Common shares outstanding were 24,816,940 at quarter-end, compared with 24,722,974 at year-end 2022.
Outlook, risks and unusual items
- Management expected topline data from the Phase 2b portion of IMPAHCT in Q2 2024, with enrollment expected to finish about seven months earlier. The filing cautions that site activation and enrollment delays make timing uncertain.
- The company entered into a $75 million at-the-market (ATM) equity sales agreement on April 5, 2023, after quarter-end. No shares had been sold under it as of May 15, 2023; any future sales could dilute existing shareholders.
- Management expects substantial future losses and says additional capital will be needed. Failure to raise funds could require delays, reductions or termination of development activities.
- Key risks include the single-candidate dependence on AV-101; uncertain clinical efficacy and tolerability; patient-enrollment and site-activation delays; regulatory and drug-device approval requirements; reliance on third-party trial operators and suppliers, including a sole-source inhaler supplier; competition; and patent protection.
- Oral imatinib showed efficacy signals in a prior PAH trial but had significant adverse events and was not approved for PAH. The filing stresses that those results and AV-101’s Phase 1 results in healthy volunteers may not predict outcomes in PAH patients.
- The company reported no material legal proceedings and no material impact from the Silicon Valley Bank closure. Management stated disclosure controls and procedures were effective at a reasonable assurance level and reported no material change in internal control over financial reporting during the quarter.
Most important facts for an investor to verify
- Confirm the issuer: the supplied filing is Aerovate Therapeutics, Inc., not Jade Biosciences, Inc.
- Check subsequent IMPAHCT enrollment, trial timing and data disclosures against the Q2 2024 expectation stated in this filing.
- Assess the cash runway using later cash-burn results and any changes to development plans; the second-half-2025 estimate is forward-looking.
- Review whether the ATM was used after May 15, 2023, and the resulting proceeds and share dilution.
- Evaluate clinical safety and efficacy evidence for inhaled AV-101 separately from prior oral imatinib results.